Epidemic poliomyelitis, post-poliomyelitis sequelae and the eradication program
Margaret M PeelMicrobiology Australia 41(4) 196-200 https://doi.org/10.1071/MA20053
Published: 20 October 2020
Abstract
Epidemics of paralytic poliomyelitis (polio) first emerged in the late 19th and early 20th centuries in the United States and the Scandinavian countries. They continued through the first half of the 20th century becoming global. A major epidemic occurred in Australia in 1951 but significant outbreaks were reported from the late 1930s to 1954. The poliovirus is an enterovirus that is usually transmitted by the faecal–oral route but only one in about 150 infections results in paralysis when the central nervous system is invaded. The Salk inactivated polio vaccine (IPV) became available in Australia in 1956 and the Sabin live attenuated oral polio vaccine (OPV) was introduced in 1966. After decades of stability, many survivors of the earlier epidemics experience late-onset sequelae including post-polio syndrome. The World Health Organization launched the global polio eradication initiative (GPEI) in 1988 based on the easily administered OPV. The GPEI has resulted in a dramatic decrease in cases of wild polio so that only Pakistan and Afghanistan report such cases in 2020. However, a major challenge to eradication is the reversion of OPV to neurovirulent mutants resulting in circulating vaccine-derived poliovirus (cVDPV). A novel, genetically stabilised OPV has been developed recently to stop the emergence and spread of cVDPV and OPV is being replaced by IPV in immunisation programs worldwide. Eradication of poliomyelitis is near to achievement and the expectation is that poliomyelitis will join smallpox as dreaded epidemic diseases of the past that will be consigned to history.
References
[1] Highley, K. (2016) Dancing in my dreams: confronting the spectre of polio. pp. 178–180, Monash University Publishing.[2] Gould, T. (1995) Part 1. The rise and fall of epidemic poliomyelitis. In A Summer Plague: Polio and its Survivors. p. 11, Yale University Press.
[3] Melnick, J.L. (1996) Current status of poliovirus infections. Clin. Microbiol. Rev. 9, 293–300.
| Current status of poliovirus infections.Crossref | GoogleScholarGoogle Scholar | 8809461PubMed |
[4] Nathanson, N. and Kew, O.M. (2010) From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am. J. Epidemiol. 172, 1213–1229.
| From emergence to eradication: the epidemiology of poliomyelitis deconstructed.Crossref | GoogleScholarGoogle Scholar | 20978089PubMed |
[5] Smallman-Raynor, M. and Cliff, A.D. (2013) The geographical spread of the 1947 poliomyelitis epidemic in England and Wales: spatial wave propagation of an enigmatic epidemiological event. J. Hist. Geogr. 40, 36–51.
| The geographical spread of the 1947 poliomyelitis epidemic in England and Wales: spatial wave propagation of an enigmatic epidemiological event.Crossref | GoogleScholarGoogle Scholar |
[6] Skern, T. (2010) 100 years poliovirus: from discovery to eradication. A meeting report. Arch. Virol. 155, 1371–1381.
| 100 years poliovirus: from discovery to eradication. A meeting report.Crossref | GoogleScholarGoogle Scholar | 20683737PubMed |
[7] Burnet, F.M. and Macnamara, J. (1931) Immunological differences between strains of poliomyelitic virus. Br. J. Exp. Pathol. 12, 57–61.
[8] Kidd, D. et al. (1996) Poliomyelitis. Postgrad. Med. J. 72, 641–647.
| Poliomyelitis.Crossref | GoogleScholarGoogle Scholar | 8944203PubMed |
[9] Kendall, F.P. (1998) Sister Elizabeth Kenny revisited. Arch. Phys. Med. Rehabil. 79, 361–365.
| Sister Elizabeth Kenny revisited.Crossref | GoogleScholarGoogle Scholar | 9552099PubMed |
[10] Weller, T.H. et al. (1952) Studies on the cultivation of poliomyelitis viruses in tissue culture. J. Immunol. 69, 645–671.
| 13022978PubMed |
[11] Salk, J.E. et al. (1954) Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines. Am. J. Public Health 44, 563–570.
| Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines.Crossref | GoogleScholarGoogle Scholar |
[12] Sabin, A.B. (1959) Present position of immunization against poliomyelitis with live virus vaccines. BMJ 1, 663–680.
| Present position of immunization against poliomyelitis with live virus vaccines.Crossref | GoogleScholarGoogle Scholar | 13629086PubMed |
[13] Halstead, L.S. and Silver, J.K. (2000) Nonparalytic polio and postpolio syndrome. Am. J. Phys. Med. Rehabil. 79, 13–18.
| Nonparalytic polio and postpolio syndrome.Crossref | GoogleScholarGoogle Scholar | 10678597PubMed |
[14] Gonzalez, H. et al. (2010) Management of postpolio syndrome. Lancet Neurol. 9, 634–642.
| Management of postpolio syndrome.Crossref | GoogleScholarGoogle Scholar | 20494327PubMed |
[15] Peel, M.M. et al. (2015) A randomized controlled trial of coenzyme Q10 for fatigue in the late-onset sequelae of poliomyelitis. Complement. Ther. Med. 23, 789–793.
| A randomized controlled trial of coenzyme Q10 for fatigue in the late-onset sequelae of poliomyelitis.Crossref | GoogleScholarGoogle Scholar | 26645517PubMed |
[16] World Health Organization (1988) Global eradication of poliomyelitis by the year 2000. Wkly. Epidemiol. Rec. 63, 161–162.
[17] Jorba, J. et al. (2019) Update on vaccine-derived poliovirus outbreaks – worldwide, January 2018 to June 2019. MMWR Morb. Mortal. Wkly. Rep. 68, 1024–1028.
| Update on vaccine-derived poliovirus outbreaks – worldwide, January 2018 to June 2019.Crossref | GoogleScholarGoogle Scholar | 31725706PubMed |
[18] Hsu, C.H. et al. (2019) Progress toward poliomyelitis eradication – Pakistan. MMWR Morb. Mortal. Wkly. Rep. 68, 1029–1033.
| Progress toward poliomyelitis eradication – Pakistan.Crossref | GoogleScholarGoogle Scholar | 31725710PubMed |
[19] Martinez, M. et al. (2019) Progress toward poliomyelitis eradication – Afghanistan. MMWR Morb. Mortal. Wkly. Rep. 68, 729–733.
| Progress toward poliomyelitis eradication – Afghanistan.Crossref | GoogleScholarGoogle Scholar | 31437144PubMed |
[20] Chard, A.N. et al. (2020) Progress toward polio eradication – worldwide. MMWR Morb. Mortal. Wkly. Rep. 69, 784–789.
| Progress toward polio eradication – worldwide.Crossref | GoogleScholarGoogle Scholar | 32584798PubMed |
[21] Parker, E.P.K. et al. (2014) Influence of enteric infections on response to oral poliovirus vaccine: a systematic review and meta-analysis. J. Infect. Dis. 210, 853–864.
| Influence of enteric infections on response to oral poliovirus vaccine: a systematic review and meta-analysis.Crossref | GoogleScholarGoogle Scholar |
[22] Hall, J.J. et al. (2019) Poliomyelitis outbreak in Papua New Guinea: health system and health security implications for PNG and Australia. Med. J. Aust. 211, 161–162.e1.
| Poliomyelitis outbreak in Papua New Guinea: health system and health security implications for PNG and Australia.Crossref | GoogleScholarGoogle Scholar | 31318056PubMed |
[23] Bandyopadhyay, A.S. et al. (2018) Immunogenicity of new primary immunization schedules with inactivated poliovirus vaccine and bivalent oral polio vaccine for the polio endgame: a review. Clin. Infect. Dis. 67, S35–S41.
| Immunogenicity of new primary immunization schedules with inactivated poliovirus vaccine and bivalent oral polio vaccine for the polio endgame: a review.Crossref | GoogleScholarGoogle Scholar | 30376081PubMed |
[24] Yeh, M.T. et al. (2020) Engineering the live-attenuated polio vaccine to prevent reversion to virulence. Cell Host Microbe 27, 736–751.
| Engineering the live-attenuated polio vaccine to prevent reversion to virulence.Crossref | GoogleScholarGoogle Scholar | 32330425PubMed |
[25] D’Souza, R.M. et al. (2002) Australia declared polio free. Commun. Dis. Intell. 26, 253–260.
[26] World Health Organization (2020) Statement of the twenty-fifth polio IHR Emergency Committee. 23 June. https://www.who.int/news-room/detail/23-06-2020-statement-of-the-25th-polio-ihr-emergency-committee
